UPS announces results of annual supply chain survey

Michael Walter | | Health Exec | Supply Chain

UPS has released the results of its eighth annual Pain in the Chain survey, which asks healthcare and life sciences logistics executives questions about various supply chain issues.

Seventy-five percent of the interviewed decision makers reported success with product security issues within the supply chain, while just 50 percent reported success with managing logistics, warehousing, and transportation costs.

The survey was conducted by research firm TNS between April and June 2015, and involved a total of 421 interviews in 16 different countries.

The full report can be read below.

Eighth UPS Pain in the Chain Survey—Survey Snapshot

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
FDA recalls 233K bottles of antidepressants due to cancer risk
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.